Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05025358
Other study ID # LP-118-CN101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date September 14, 2021
Est. completion date July 30, 2024

Study information

Verified date October 2022
Source Guangzhou Lupeng Pharmaceutical Company LTD.
Contact Yue Shen, PhD
Phone 86571-81999616
Email yshen@lupengbio.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase I, multi-center, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-118 in patients with advanced malignancies, including solid tumors and lymphomas. LP-118 is a BCL-2/BCL-XL small molecule inhibitor.


Description:

LP-118 is an oral selective BCL-2 inhibitor with tuned BCL-XL activity, aiming to improve antitumor efficacy and reduce the risk of thrombocytopenia. Clinical development of LP-118 includes targeting of relapsed or refractory hematological malignancies and solid tumors. This is a multi-center, open-label, Phase 1 dose escalation study of LP-118 in patients with advanced malignancies, including advanced/metastatic solid tumors and relapsed/refractory B cell, T/NK cell lymphomas, to determine the safety, tolerability, pharmacokinetics profile and preliminary anti-tumor efficacy. Upon completion of the Phase 1 dose escalation study and establishment of maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), the dose expansion study will be implemented in patients with protocol designated type of disease.


Recruitment information / eligibility

Status Recruiting
Enrollment 96
Est. completion date July 30, 2024
Est. primary completion date December 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subjects with histologically or cytologically confirmed malignancy, including either of the following disease: relapsed or refractory lymphomas with at least one measurable disease based on Lugano 2014 criteria; or advanced or metastatic solid tumors based on RECIST V1.1 criteria. - Subjects have a life expectancy of =12 weeks, and Eastern Cooperative Oncology Group (ECOG) performance score less than or equal to 1. - Subjects must have adequate bone marrow function independent of blood transfusion or growth factor support per local laboratory reference range at Screening. - Subjects must have adequate coagulation, renal, and hepatic function, per local laboratory reference range at Screening. - All acute toxicity from previous anti-tumor treatment or surgery has been alleviated to NCI CTCAE 5.0 = Grade 1. - All enrolled subjects should take medically approved contraceptives during the entire treatment period and within 90 days after the end of treatment. - Volunteer and sign informed consent, willing to follow trial protocol. Exclusion Criteria: - Subjects who have undergone allogeneic or autologous hematopoietic stem cell transplantation or CAR-T cell therapy (except for lymphoma patients who had received autologous stem cell transplantation or CAR-T cell therapy before 90 days of the first dose of LP-118). - Subjects who have received the following treatments within 4 weeks or 5 half-lives before the first dose of study drug: - Antitumor therapies including myelosuppressive chemotherapy, targeted therapy, biological therapy and/or immunotherapy; - Any investigational treatment; - Patients who have undergone major surgery, severe trauma or radiotherapy. - Subjects who have received the following treatments within 1 week before the first dose of study drug: - Steroids or traditional herbal medicine for antitumor purposes; - Strong and moderate CYP3A inhibitors and inducers, grapefruit and grapefruit juice; - Any medications that can cause QTc interval prolongation or torsional tachycardia. - Solid tumor patients with ITP or AIHA. - Subjects with known bleeding disease or with a history of non-chemotherapy induced thrombocytopenic bleeding or ineffective platelet transfusion within 1 year before the first dose of study drug. - Subjects with uncontrollable or CTCAE = grade 2 gastrointestinal bleeding occurred within 90 days before the first dose of study drug. - Subjects have received the therapeutic dose of anticoagulant or antiplatelet drugs within 1 week before the first dose of study drug. - Subjects have any serious and/or uncontrolled systemic disease. - Subjects have poor cardiovascular function, in line with New York Heart Association (NYHA) cardiac function classification = 2 or QTcF greater than 450ms (male) or 470ms (female) on = 3 independent ECG. - Subjects have disease states where clinical manifestations may be difficult to control, including but not limited to HIV, HBV, HCV, syphilis positive or active bacterial and fungal infections. - Lymphoma with primary central nervous system (CNS) malignancy or any disease affects the CNS. - Any gastrointestinal conditions that may severely affect the study drug absorption or pharmacokinetic parameters. - Subjects who have known severe allergies to study drugs or any excipients. - Subjects who have evidence of a second primary tumor.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LP-118 tablet
Subjects will administered orally with LP-118 tablet at the designated dose once daily, using approximately 240 mL of water during a meal or within 30 minutes after a meal, 28 days per cycle. The treatment will continue until progressive disease, unacceptable toxicity, etc.

Locations

Country Name City State
China Guangdong Provincial People's Hospital Guangzhou Guangdong
China The First Affiliated Hospital of Jinan University Guangzhou Guangdong
China First Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang
China Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Guangzhou Lupeng Pharmaceutical Company LTD.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (MTD) The highest dose that does not cause unacceptable side effects or overt toxicities which will be assessed by NCI CTCAE v5.0. Up to 24 months
Primary Adverse events The incidence and severity of adverse events as assessed by NCI CTCAE v5.0. Up to 24 months
Primary Recommended phase II dose (RP2D) The safe dose that demonstrates the greatest pharmacological activity. Up to 24 months
Primary PK evaluation of area under the plasma concentration versus time curve (AUC) of LP-118 AUC indicates the extent of exposure to LP-118 and its clearance rate from the body. Up to Cycle 6 (each cycle is 28 days)
Primary PK evaluation of peak plasma concentration (Cmax) of LP-118 Cmax indicates the highest drug concentration in the blood after LP-118 administration. Up to Cycle 6 (each cycle is 28 days)
Primary PK evaluation of time to maximum concentration (Tmax) of LP-118 Tmax indicates the time taken to reach the maximum drug concentration (i.e. Cmax). Up to Cycle 6 (each cycle is 28 days)
Secondary Overall response rate (ORR) The proportion of patients who have a partial or complete response after LP-118 treatment. Up to 24 months
Secondary Duration of response (DOR) The time from first documented response to disease progression or death. Up to 24 months
Secondary Progression-free survival (PFS) The time from first dose to disease progression or death, whichever occurs first. Up to 24 months
Secondary Overall survival The time from first dose to the date of death from any cause. Up to 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT05580991 - Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors Phase 1
Recruiting NCT05691608 - MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2 N/A
Active, not recruiting NCT02846038 - Understanding Communication in Healthcare to Achieve Trust (U-CHAT)
Recruiting NCT05159388 - A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors Phase 1/Phase 2
Completed NCT03181854 - Randomized Controlled Trial of Integrated Early Palliative Care N/A
Recruiting NCT05981703 - A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors Phase 1
Recruiting NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors Phase 1
Recruiting NCT04107311 - Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients
Active, not recruiting NCT04078152 - Durvalumab Long-Term Safety and Efficacy Study Phase 4
Completed NCT02250157 - A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies Phase 1
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT03943004 - Trial of DFP-14927 in Advanced Solid Tumors Phase 1
Recruiting NCT06036836 - Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) Phase 2
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting NCT05798546 - Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02) Phase 1
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT00479128 - Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors Phase 1
Recruiting NCT04143789 - Evaluation of AP-002 in Patients With Solid Tumors Phase 1/Phase 2
Not yet recruiting NCT04550663 - NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors Phase 1
Completed NCT03980041 - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) Phase 2